This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Concentra Stock Slips Despite Deal to Acquire Pivot Onsite Innovations
by Zacks Equity Research
CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
by Zacks Equity Research
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
DGX delivers solid top-line growth in the first quarter of 2025.
Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network
by Zacks Equity Research
Veeva Systems, Hims & Hers Health and Butterfly Network are part of the Zacks Industry Outlook article.
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors.
ECL Stock Gains Following 5% Trade Surcharge in the United States
by Zacks Equity Research
Ecolab announces a 5% U.S. trade surcharge to offset rising costs.
Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?
by Zacks Equity Research
GeneDx is expected to have continued the strong 2024 momentum across all metrics in the first quarter of 2025.
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities.
3 Medical Info Systems Stocks to Ride the AI Wave in Trump Tariff Era
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like VEEV, HIMS and BFLY are expected to gain from the Stargate Project and provide relief amid tariff tension.
Wall Street Bulls Look Optimistic About Veeva (VEEV): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock
by Zacks Equity Research
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ALGN Gears Up for Q1 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's first-quarter 2025 results are likely to reflect the strength in its Clear Aligner business.
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings
by Zacks Equity Research
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
Abbott Q1 Earnings Beat, Sales Miss, Stock Falls in Pre-Market
by Zacks Equity Research
ABT delivers a strong underlying base business performance for the first quarter of 2025.
CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm
by Zacks Equity Research
Ceribell secures FDA clearance for Clarity algorithm in pediatric patients, expanding rapid seizure detection capabilities and enhancing critical care efficiency.
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
by Zacks Equity Research
LH's first-quarter 2025 performance is likely to have benefited from both its Dx and BLS businesses.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings
by Zacks Equity Research
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's first-quarter 2025 performance.
LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
by Zacks Equity Research
Lifeward launches ReWalk 7 in the United States, offering advanced mobility, greater control and smarter walking for individuals with spinal cord injuries.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $222.72, moving -0.42% from the previous trading session.
HealthEquity Stock Plunges 13% YTD: Is It Time to Exit or Hold?
by Zacks Equity Research
HQY stock is down more than 13% YTD amid cyber threats and rising costs, but strong HSA fundamentals remain. Is it time to hold or fold? Let's break it down.
Merit Medical Stock Slips Despite the Launch of New Ventrax System
by Zacks Equity Research
MMSI launches the Ventrax Delivery System, enhancing pulmonary access procedures with improved control, precision, and efficiency for interventionalists.
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
by Zacks Equity Research
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
Intuitive Surgical Shares May Rise as FDA Clears SureForm 45 Stapler
by Zacks Equity Research
ISRG secures FDA clearance for the first stapler designed for single-port robotic surgery, advancing minimally invasive procedures and enhancing surgical precision.